Management

---

President &
Chief Executive Officer

Dr. Siddhesh Angle's career in musculoskeletal research & development spans 15 years. Dr. Angle played an integral role in the acquisition of a synthetic biomaterials start-up by Zimmer Biomet. He was then R&D Manager for their Global Biologics business and has successfully commercialized several orthopedic medical devices and combination therapies.  

Chief Technology Officer

10+ years of experience in formulating drug delivery

mechanisms , including nanocarriers for targeted drug delivery to colon cancer cells and targeted delivery

systems capable of crossing the BBB and targeting microglia to mitigate TBI. Oversees Regenosine's 

drug formulation development, analytical method development and characterization of adenosine loaded liposomes

and other synthetic formulations for treating OA.